SCHEMBL2923903

SCHEMBL2923903

CC(C)c1ccc(C(=O)CCCCl)cc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP5 P45974 1/20 0.64
POLB P06746 1/20 0.50
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
HSD17B3 P37058 3/20 0.44
EGFR P00533 1/20 0.44
ERBB2 P04626 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
MPI P34949 1/20 0.44
HTR7 P34969 1/20 0.43
CYP2C9 P11712 1/20 0.43
RXRA P19793 1/20 0.43
RXRB P28702 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1855772 0.89 USP5 (0.68) USP5POLBMEN1KMT2AL3MBTL1
SCHEMBL4871741 0.89 USP5 (0.72) USP5POLBMEN1KMT2AL3MBTL1
SCHEMBL8072880 0.86 USP5 (0.47) USP5L3MBTL1NPC1RAB9AHSD17B3
SCHEMBL3682043 0.86 USP5 (0.47) USP5L3MBTL1NPC1RAB9AHSD17B3
SCHEMBL27724305 0.85 USP5 (0.46) USP5L3MBTL1NPC1RAB9AHSD17B3
SCHEMBL3671743 0.85 USP5 (0.50) USP5POLBL3MBTL1NPC1RAB9A
SCHEMBL30089581 0.85 USP5 (0.85) USP5POLBMEN1KMT2AL3MBTL1
SCHEMBL5566974 0.84 USP5 (0.66) USP5POLBMEN1KMT2AL3MBTL1
SCHEMBL7790180 0.83 USP5 (0.45) USP5L3MBTL1NPC1RAB9AHSD17B3
SCHEMBL3668961 0.83 EPHX1 (0.49) USP5L3MBTL1NPC1RAB9AHSD17B3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10004701-B2 Methods and compositions for treating infection UNIVERSITY OF ROCHESTER (US) 2018-06-26 US disclosed
US-10004701-B2 Methods and compositions for treating infection UNIVERSITY OF ROCHESTER (US) 2018-06-26 US disclosed
US-10004701-B2 Methods and compositions for treating infection UNIVERSITY OF ROCHESTER (US) 2018-06-26 US disclosed
US-20170065540-A1 METHODS AND COMPOSITIONS FOR TREATING INFECTION UNIVERSITY OF ROCHESTER (US) 2017-03-09 US disclosed
US-20170065540-A1 METHODS AND COMPOSITIONS FOR TREATING INFECTION UNIVERSITY OF ROCHESTER (US) 2017-03-09 US disclosed
US-20170065540-A1 METHODS AND COMPOSITIONS FOR TREATING INFECTION UNIVERSITY OF ROCHESTER (US) 2017-03-09 US disclosed
US-20150238473-A1 METHODS AND COMPOSITIONS FOR TREATING INFECTION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-08-27 US disclosed
US-20150238473-A1 METHODS AND COMPOSITIONS FOR TREATING INFECTION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-08-27 US disclosed
US-20150238473-A1 METHODS AND COMPOSITIONS FOR TREATING INFECTION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-08-27 US disclosed
US-8269033-B2 Process for carbonylating phenylalkyl derivatives by means of carbon monoxide SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2012-09-18 US disclosed
US-6348597-B2 INTERMEDIATE P-CYCLOPROPANOYL CUMENE COMPOUNDS AND DERIVATIVES, OPTIONALLY HAVING A 3-HYDROXY GROUP; 1-(BENZOYLALKYL)-4-(DIPHENYLMETHOXY)-PIPERIDINE COMPOUNDS AND 1-(A-HYDROXYBENZYLALKYL)-4-(DIPHENYLALKENYL)-PIPERIDINES MERRELL PHARMACEUTICALS, INC. 2002-02-19 US disclosed
US-6340761-B1 AMINATION AND DEHYDROHALOGENATION WITH PIPERIDINE COMPOUNDS MERRELL PHARMACEUTICALS INC. 2002-01-22 US disclosed
US-20020007085-A1 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives MERRELL PHARMACEUTICALS INC. 2002-01-17 US disclosed
US-20010031895-A1 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives MERRELL DOW PHARMACEUTICALS INC. 2001-10-18 US disclosed
US-20010021791-A1 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives MERRELL PHARMACEUTICALS INC. 2001-09-13 US disclosed
US-20010020114-A1 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives MERRELL PHARMACEUTICALS INC. 2001-09-06 US disclosed
US-20010018521-A1 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives MERRELL PHARMACEUTICALS INC. 2001-08-30 US disclosed
US-6242606-B1 REACTING A A,A-DIMETHYLPHENYLACETIC ACID AMIDE WITH A W-HALO COMPOUND PRODUCES W'-HALO-A-KETO-A,A-DIMETHYLPHENYLACETIC ACID AMIDE AND REACTING IT WITH A PIPERIDINE COMPOUND; 2-(4-(4-CHLORO-BUTYRYL)-PHENYL)-2-METHY-PROPIONIC ACID MERRELL PHARMACEUTICALS INC. 2001-06-05 US disclosed
US-20010000038-A1 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives CHATTEM INC. 2001-03-15 US disclosed
US-6147216-A Intermediates useful for the preparation of antihistaminic piperidine derivatives MERRELL PHARMACEUTICALS INC. (US) 2000-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010000038-A1 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives HRH1, HRH3, HRH4 USP5 1497/4885POLB 1784/4885MEN1 2722/4885
US-20010020114-A1 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives HRH1, HRH3, HRH4 USP5 1505/4885POLB 1549/4885MEN1 2716/4885
US-20010021791-A1 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives HRH1, HRH3, HRH4 USP5 1362/4885POLB 1947/4885MEN1 2111/4885
US-20010031895-A1 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives HRH1, HRH4, HRH3 USP5 1453/4885POLB 2041/4885MEN1 2358/4885
US-20150238473-A1 METHODS AND COMPOSITIONS FOR TREATING INFECTION MMP8, IFNG, MPO USP5 617/4885POLB 1335/4885MEN1 3878/4885
US-20010018521-A1 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives HRH1, HRH3, HRH4 USP5 1388/4885POLB 1839/4885MEN1 2708/4885
US-20170065540-A1 METHODS AND COMPOSITIONS FOR TREATING INFECTION MMP8, IFNG, MPO USP5 617/4885POLB 1335/4885MEN1 3878/4885
US-20020007085-A1 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives HRH1, HRH3, HRH4 USP5 1344/4885POLB 1962/4885MEN1 2320/4885
US-10004701-B2 Methods and compositions for treating infection MMP8, IFNG, MPO USP5 617/4885POLB 1335/4885MEN1 3878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.